News | December 09, 2009

Linacs to Generate Nuclear Isotopes for Canada, Not Reactors

December 9, 2009 - An expert panel reviewing Canadian medical isotope productions selected electron beam technology as a superior approach to accelerator-based isotope production.

The panel has recommended the Canadian government make an investment in linear accelerator (linac) technology to address the country’s shrinking isotope supply.

Noting significant vulnerabilities in Canada’s radioisotope technetium-99 supply (used to scan patients for cancer and heart ailments), following the May 2009 shutdown of the NRU reactor at Chalk River, the Canadian Government called on an expert panel in July 2009 to review and recommend options for securing supply and alternative production of Tc-99. Over 20 "expression of interest" proposals from North American companies were considered.

Iotron Industries, an irradiation services using electron beam technology, will provide an alternative to nuclear production, at a very competitive cost. Iotron’s technology is characterized as linac, based on MO-100 transmutation, and was specifically singled out by the Canadian Medical Isotope Review Panel as a superior approach to accelerator based isotope production.

The benefits of linac technology identified in the panel’s report are:
· Two facilities could service all of Canada’s needs
· Relatively short timeline required to first production of badly needed isotopes
· Requires a very modest price increase and is price competitive with all other options
· Generates no nuclear waste
· Capital cost is much lower than any other facilities capable of producing long lasting isotopes

The Chalk River reactor is 52 years old and supplies up to 80 percent of the medical isotopes used in Canada and 40 percent of those needed globally. Canadian doctors warn of the quickly growing risk of compromised patient diagnosis and treatment should the shortage continue into the future.

Iotron President Lloyd Scott confirms that a great deal of progress has been made by Iotrons’ research and development efforts on the high power target, extraction, purification, and recycling processes since the submission of the expression of interest in July 2009.

Iotron will commence open communication with the Canadian government next week to begin the process of initiating action on the panel’s recommendation for investment.

For more information: www.iotron.com

Related Content

ARTMS Products Inc. and GE Healthcare Team Up to Expand Cyclotron-Produced Radioisotopes
News | Radiopharmaceuticals and Tracers| August 30, 2017
ARTMS Products Inc. signed a strategic partnership with GE Healthcare around ARTMS’ proprietary QUANTM99 Irradiation...
Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18
News | Radiopharmaceuticals and Tracers| May 22, 2017
Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced the signing of a...
Australian Team Finds New Method for Producing PET Radiotracers in Higher Radiochemical Yields
News | Radiopharmaceuticals and Tracers| April 28, 2017
Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the development of a new...
University of Missouri Research Reactor Files to Start U.S. Production of Medical Isotopes
News | Radiopharmaceuticals and Tracers| April 13, 2017
The University of Missouri Research Reactor (MURR) and its partners Nordion and General Atomics (GA), announced in...
IBA Molecular and Mallinckrodt Nuclear Medicine Merge to Become Curium
News | Radiopharmaceuticals and Tracers| April 11, 2017
April 11, 2017 — IBA Molecular announced that it has merged with previous acquisition Mallinckrodt...
GE Healthcare, HealthTrust, supply agreement, nuclear imaging, radiopharmaceuticals
News | Radiopharmaceuticals and Tracers| April 05, 2017
April 5, 2017 — GE Healthcare has signed an agreement with HealthTrust, a group purchasing organization headquartered
Nuclear cardiology, nuclear imaging, radiotracer production, automated radiosynthesis module, myocardial perfusion imaging
Feature | Radiopharmaceuticals and Tracers| March 01, 2017 | Anamika Kumari
Huge portions of the globally produced radiotracers find their origin within geographically centralized, commercial r
News | Radiopharmaceuticals and Tracers| January 17, 2017
NorthStar Medical Technologies LLC has received additional matching funds from the U.S. Department of Energy’s National...
SNMMI Develops USP Recommendations for Compounded Sterile Radiopharmaceuticals
News | Radiopharmaceuticals and Tracers| December 28, 2016
December 28, 2016 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has developed United States Pharmac
NAS report, National Academies of Sciences Engineering and Medicine, Mo-99 production, highly enriched uranium, HEU, SNMMI
News | Radiopharmaceuticals and Tracers| October 28, 2016
The National Academies of Sciences, Engineering, and Medicine (NAS) have released a report on the state of molybdenum-...
Overlay Init